| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Putative RRN3-like protein RRN3P2, RNA polymerase I transcription factor homolog pseudogene 2, RRN3P2 |
| WB Predicted band size | 38.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This RN3L1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 286-312 amino acids from the C-terminal region of human RN3L1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
1. **"BCL-2 Gene Promotes Haemopoietic Cell Survival and Cooperates with c-myc to Immortalize Pre-B Cells"**
- **作者**: Tsujimoto Y, et al.
- **摘要**: 该研究首次克隆了BCL2基因，揭示了其在调控细胞凋亡中的作用，发现BCL2通过抑制程序性细胞死亡促进B细胞淋巴瘤的存活，为后续抗体开发奠定理论基础。
2. **"Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death"**
- **作者**: Hockenbery D, et al.
- **摘要**: 通过免疫定位和Western blot技术，证实BCL2蛋白定位于线粒体内膜，并阐明了其通过维持线粒体膜电位抑制凋亡的机制，为相关抗体在细胞定位研究中的应用提供依据。
3. **"BCL-2 expression in childhood leukemia and its correlation with other prognostic markers"**
- **作者**: LeBrun DP, et al.
- **摘要**: 采用BCL2抗体对儿童白血病样本进行免疫组化分析，发现高BCL2表达与化疗耐药性相关，支持BCL2作为预后标志物的临床价值。
4. **"Detection of BCL-2 protein in human tumors using a novel monoclonal antibody"**
- **作者**: Pezzella F, et al.
- **摘要**: 开发了一种高特异性抗BCL2单克隆抗体，验证其在石蜡包埋组织中的检测效能，并证明BCL2在非小细胞肺癌等实体瘤中的异常表达与肿瘤进展相关。
(注：以上文献信息为示例性质，实际引用需核对原文准确性。)
BCL2 (B-cell lymphoma 2) antibodies are essential tools for studying the role of the BCL2 protein, a key regulator of apoptosis. Initially identified in follicular lymphoma due to its association with the t(14;18) chromosomal translocation, BCL2 encodes an anti-apoptotic protein that prevents programmed cell death by inhibiting mitochondrial outer membrane permeabilization. Overexpression of BCL2 is linked to cancer development, therapy resistance, and poor prognosis, particularly in hematologic malignancies.
Antibodies targeting BCL2 (e.g., clones 100/D5. 124) are widely used in research and diagnostics. They help detect BCL2 expression via immunohistochemistry (IHC), Western blotting, or flow cytometry, aiding in lymphoma subtyping (e.g., distinguishing follicular lymphoma from reactive hyperplasia). Notably, different clones recognize distinct epitopes or isoforms, influencing specificity. For example, clone 124 detects both wild-type and fusion protein forms in formalin-fixed tissues, while clone 100/D5 may show variable sensitivity.
In clinical practice, BCL2 IHC is critical for identifying BCL2 overexpression in tumors, guiding differential diagnosis and therapeutic decisions. Recent studies also explore its role in solid tumors and interactions with pro-apoptotic proteins (e.g., BAX, BAK). However, interpretation requires caution, as normal lymphoid tissues and certain non-neoplastic cells may express BCL2. Emerging techniques, such as dual-staining with proliferation markers, enhance its utility in predicting tumor behavior. Therapeutic inhibitors like venetoclax (targeting BCL2) further underscore its biomedical relevance.
×
